Van Vulpen M, De Leeuw A A C, Raaymakers B W, Van Moorselaar R J A, Hofman P, Lagendijk J J W, Battermann J J
Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands.
BJU Int. 2004 Jan;93(1):36-41. doi: 10.1111/j.1464-410x.2004.04551.x.
OBJECTIVE: To report an interim clinical evaluation of combined external beam irradiation (EBRT) and interstitial or regional hyperthermia in the treatment of locally advanced prostate cancer. PATIENTS AND METHODS: From 1997 to 2001, 26 patients with T3-4/NX/0M0 prostate carcinoma were treated with a combination of conformal EBRT and hyperthermia. Fourteen patients received five weekly regional hyperthermia treatments within an optimization (phase II) study, using the coaxial transverse electrical magnetic system. Twelve patients received one interstitial hyperthermia treatment within a feasibility study (phase I), using the multi-electrode current source system. Irradiation was delivered using a conformal three-field technique, administering 70 Gy in 2-Gy fractions in 7 weeks. RESULTS: The mean initial prostate-specific antigen level was 26 ng/mL. Three patients had a T4 and 23 a T3 tumour; the tumours were classified as well (four), moderately (16) and poorly (six) differentiated. The mean follow-up was 36 months. In the combined treatments there was no toxicity of more than grade 2. In regional hyperthermia the mean index temperature (T90 and T50, i.e. exceeded by 90% and 50% of the measurements) was 40.2 degrees C and 40.8 degrees C, and for interstitial hyperthermia 39.4 degrees C and 41.8 degrees C, respectively. All patients survived; seven patients had a biochemical relapse (27%), three in the regional and four in the interstitial group. The actuarial probability of freedom from biochemical relapse was 70% at 36 months for all patients together, 79% for regional and 57% for interstitial. No factors were found that could be used to predict relapse. CONCLUSIONS: The clinical outcome in these patients with advanced localized prostate cancer seems to compare favourably with most series using irradiation alone, and the treatment caused no severe complications.
目的:报告体外束照射(EBRT)联合组织间或区域热疗治疗局部晚期前列腺癌的中期临床评估结果。 患者与方法:1997年至2001年,26例T3-4/NX/0M0期前列腺癌患者接受了适形EBRT与热疗联合治疗。14例患者在一项优化(II期)研究中,使用同轴横向电磁系统,每周接受5次区域热疗。12例患者在一项可行性研究(I期)中,使用多电极电流源系统,接受1次组织间热疗。采用适形三野技术进行照射,7周内给予70 Gy,每次2 Gy。 结果:初始前列腺特异性抗原平均水平为26 ng/mL。3例患者为T4期肿瘤,23例为T3期肿瘤;肿瘤分级为高分化(4例)、中分化(16例)和低分化(6例)。平均随访时间为36个月。联合治疗中无超过2级的毒性反应。区域热疗的平均指标温度(T90和T50,即90%和50%的测量值超过该温度)分别为40.2℃和40.8℃,组织间热疗分别为39.4℃和41.8℃。所有患者均存活;7例患者出现生化复发(27%),区域热疗组3例,组织间热疗组4例。所有患者36个月时无生化复发的精算概率为70%,区域热疗组为79%,组织间热疗组为57%。未发现可用于预测复发的因素。 结论:这些局部晚期前列腺癌患者的临床结局似乎优于大多数单纯使用放疗的系列研究,且该治疗未引起严重并发症。
Int J Radiat Oncol Biol Phys. 1997-3-15
Int J Radiat Oncol Biol Phys. 1993-5-20
Int J Radiat Oncol Biol Phys. 2002-5-1
Int J Radiat Oncol Biol Phys. 2003-11-1
Nanomaterials (Basel). 2022-5-25
Cancers (Basel). 2022-1-13
Front Oncol. 2017-6-30
Proc SPIE Int Soc Opt Eng. 2009-2-23